Rene Gonzalez Selected Research

Interleukin-2 (IL2)

1/2019	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
12/2016	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
1/2016	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
10/2013	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
12/2011	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
6/2011	gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
12/2009	Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
12/2005	Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
1/2005	A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
1/2002	A phase II study of neoadjuvant biochemotherapy for stage III melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rene Gonzalez Research Topics

Disease

98	Melanoma (Melanoma, Malignant) 10/2022 - 01/2002
40	Neoplasms (Cancer) 02/2022 - 01/2007
8	Disease Progression 10/2018 - 11/2009
6	Body Weight (Weight, Body) 10/2019 - 08/2010
6	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2009
5	Fatigue 08/2015 - 06/2009
4	Neutropenia 11/2018 - 01/2010
4	Brain Neoplasms (Brain Tumor) 10/2018 - 06/2011
3	Pneumonia (Pneumonitis) 01/2021 - 08/2015
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 01/2012
3	Fever (Fevers) 10/2019 - 02/2011
3	Arthralgia (Joint Pain) 10/2019 - 02/2011
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 04/2011
3	Colitis 11/2018 - 08/2015
3	Thrombocytopenia (Thrombopenia) 06/2014 - 06/2009
3	Carcinogenesis 10/2012 - 09/2011
2	Exanthema (Rash) 10/2019 - 08/2014
2	Myalgia 08/2015 - 08/2014
2	Nausea 08/2014 - 02/2011
2	Circulating Neoplastic Cells 04/2010 - 02/2006
1	Lung Injury 01/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Infections 01/2021
1	Erythema Nodosum 10/2019
1	Necrosis 11/2018

Drug/Important Bio-Agent (IBA)

22	IpilimumabIBA 10/2022 - 08/2010
13	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 01/2012
11	NivolumabIBA 10/2022 - 08/2014
11	VemurafenibIBA 01/2020 - 12/2011
11	Interleukin-2 (IL2)IBA 01/2019 - 01/2002
9	trametinibIBA 01/2020 - 08/2012
8	Peptides (Polypeptides)IBA 02/2022 - 12/2011
7	Type 1 Melanocortin ReceptorIBA 02/2022 - 11/2018
7	Pharmaceutical PreparationsIBA 01/2019 - 04/2009
6	LactamsIBA 01/2022 - 01/2019
6	dabrafenibIBA 01/2018 - 11/2012
6	Dacarbazine (DIC)FDA LinkGeneric 08/2014 - 05/2008
5	alpha-MSHIBA 02/2022 - 01/2019
5	AcidsIBA 02/2022 - 01/2020
5	pembrolizumabIBA 12/2021 - 08/2014
5	Immune Checkpoint InhibitorsIBA 01/2019 - 12/2016
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 01/2007
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2016 - 01/2005
5	Imatinib Mesylate (Gleevec)FDA Link 05/2015 - 01/2007
5	Monoclonal AntibodiesIBA 01/2014 - 03/2010
4	triazacyclononaneIBA 01/2022 - 01/2020
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 06/2010
4	CTLA-4 AntigenIBA 01/2019 - 08/2010
4	AntibodiesIBA 08/2014 - 11/2008
4	Temozolomide (Temodar)FDA LinkGeneric 10/2012 - 01/2005
3	Melanocyte-Stimulating Hormones (MSH)IBA 01/2022 - 11/2019
3	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2022 - 01/2020
3	cobimetinibIBA 01/2020 - 08/2014
3	LigandsIBA 01/2019 - 08/2014
3	SurvivinIBA 05/2015 - 04/2009
3	Allovectin-7IBA 01/2011 - 12/2006
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2010 - 06/2009
2	AlbuminsIBA 02/2022 - 01/2010
2	Chelating AgentsIBA 12/2020 - 01/2020
2	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 12/2020 - 01/2020
2	RNA (Ribonucleic Acid)IBA 07/2020 - 01/2007
2	Interleukin-8 (Interleukin 8)IBA 01/2019 - 10/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 11/2008
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2018 - 10/2012
2	Messenger RNA (mRNA)IBA 01/2018 - 11/2005
2	sepantroniumIBA 05/2015 - 02/2011
2	Biomarkers (Surrogate Marker)IBA 10/2012 - 04/2010
2	Small Interfering RNA (siRNA)IBA 10/2012 - 02/2012
2	HLA-A*02:01 antigenIBA 12/2011 - 08/2010
2	Protein Subunit VaccinesIBA 06/2011 - 08/2010
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2010 - 11/2005
2	Sorafenib (BAY 43-9006)FDA Link 06/2009 - 05/2008
2	Transforming Growth Factor beta (TGF-beta)IBA 06/2009 - 10/2007
2	phosphomannopentaose sulfateIBA 11/2008 - 02/2008
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 02/2022
1	Ethylene Glycol (Monoethylene Glycol)IBA 01/2022
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022
1	Chemokine CXCL10IBA 12/2021
1	Toll-Like Receptor 9IBA 12/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	HLA-A Antigens (HLA-A)IBA 01/2021
1	(2-boronoethyl)-cysteineIBA 01/2021
1	ArginaseIBA 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2021
1	phenylalanylarginineIBA 12/2020
1	MetalsIBA 01/2020
1	GSK2141795IBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	SteroidsIBA 01/2019
1	atezolizumabIBA 01/2019
1	CytokinesIBA 01/2019
1	Radioisotopes (Radionuclides)IBA 11/2018

Therapy/Procedure

43	Therapeutics 01/2022 - 10/2007
13	Drug Therapy (Chemotherapy) 11/2017 - 01/2002
9	Immunotherapy 01/2021 - 04/2009
5	Lymph Node Excision (Lymph Node Dissection) 05/2014 - 01/2005
2	Intravenous Infusions 11/2017 - 11/2009
2	Radiotherapy 01/2014 - 04/2011
2	Biological Therapy 04/2010 - 12/2009
1	Precision Medicine 01/2022